Core Viewpoint - The stock of Jin Hai Medical Technology (02225) rose over 6% following the announcement of a collaboration with Medtronic China to launch a new navigation-based spinal endoscopy technology during the 8th China International Import Expo [1] Group 1: Company Performance - Jin Hai Medical's stock increased by 6.19%, reaching HKD 1.2, with a trading volume of HKD 29.22 million [1] Group 2: Industry Developments - The 8th China International Import Expo and Hongqiao International Economic Forum commenced in Shanghai on November 5 [1] - During the expo, Jin Hai Medical will jointly unveil innovative navigation-based spinal endoscopy technology with Medtronic China, aimed at enhancing precision and intelligence in spinal surgeries [1] - The new technology is expected to shorten the learning curve for clinicians in spinal endoscopy techniques and promote more efficient and widespread clinical applications in the future [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月 ...

Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Core Viewpoint - The company is actively preparing to participate in the 8th China International Import Expo in November 2025, showcasing its latest innovative technology in spinal surgery [1] Group 1: Company Developments - The company's indirect wholly-owned subsidiary, Shanghai Jinhai Medical Technology Co., Ltd., is involved in the preparations for the expo [1] - During the expo, the company will collaborate with Medtronic China Orthopedic and Neurosurgery Group to launch a new navigation-based spinal endoscopy technology [1] Group 2: Industry Impact - The new technology is expected to enhance precision and intelligence in spinal surgery, potentially revolutionizing the field [1] - It aims to shorten the learning curve for clinicians in spinal endoscopy techniques, promoting more efficient and widespread clinical applications in the future [1]

Core Points - The company Jin Hai Medical Technology (02225) is preparing to participate in the 8th China International Import Expo (CIIE) scheduled for November 5-10, 2025, in Shanghai [1] - During the expo, Jin Hai Medical will jointly launch innovative navigation-based spinal endoscopy technology with Medtronic China, aimed at enhancing precision and intelligence in spinal surgeries [1] - Medtronic is a leading global medical technology company, operating in over 150 countries with more than 90,000 employees [1][2] Company Overview - Medtronic's primary business includes the development, manufacturing, distribution, and sales of medical therapies and services in cardiovascular, neuroscience, surgical, and diabetes fields [2] - Medtronic has established production bases in Shanghai, Changzhou, and Chengdu, China [2] - Since the first CIIE in 2018, Medtronic has participated in the event for seven consecutive years, leveraging its influence to showcase and accelerate the application of its latest innovative medical technologies and products [2]

Core Viewpoint - The company Jin Hai Medical Technology (02225) is preparing to participate in the 8th China International Import Expo (CIIE) from November 5 to 10, 2025, in Shanghai, where it will jointly launch innovative navigation-based spinal endoscopy technology with Medtronic China [1] Group 1: Company Developments - Jin Hai Medical's subsidiary is actively organizing its participation in the CIIE, showcasing its commitment to innovation in spinal surgery technology [1] - The new technology aims to enhance precision and intelligence in spinal surgeries, potentially reducing the learning curve for clinicians and promoting broader clinical application [1] Group 2: Medtronic Overview - Medtronic, a global leader in medical technology, operates in over 150 countries and has more than 90,000 employees [1] - Medtronic's primary business areas include cardiovascular disease, neuroscience, surgical technologies, and diabetes, with manufacturing bases in Shanghai, Changzhou, and Chengdu [2] - Medtronic has participated in the CIIE for seven consecutive years since its inception in 2018, leveraging the expo's influence to accelerate the application of its latest innovative medical technologies and products [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （股份代號：2225） （於開曼群島註冊成立的成員有限責任公司） 自願公告－業務發展最新情況 本公告乃由今海醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在向其股東及潛在投資者提供有關本集團的業務近期發展最新情況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司之間接全資附屬公司上海 今海醫療科技有限公司（「今海醫療」）正在積極籌辦參加於二零二五年十一月五 日至十日在中國（「中國」）上海舉辦的第八屆中國國際進口博覽會（「進博會」）。 於第八屆進博會期間，今海醫療將與美敦力中國骨科與神外業務集團（「美敦力中 國」）聯合發佈最新研發的導航下脊柱內鏡創新技術，該技術預計可應用於脊柱外 科手術，預期將為脊柱手術的精準化與智能化發展開闢全新路徑，縮短臨床醫生 在脊柱內鏡技術上的學習 ...

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月底 ...

Core Viewpoint - The announcement details the resignation of Ms. Zheng Yuan from her roles as company secretary, authorized representative, and legal process agent, effective September 29, 2025, and the appointment of Mr. Huang Wenyau to fill these positions on the same date [1] Group 1 - Ms. Zheng Yuan has resigned from her positions within the company [1] - Mr. Huang Wenyau has been appointed to succeed Ms. Zheng Yuan [1] - Both changes will take effect on September 29, 2025 [1]

Core Viewpoint - The company announced the resignation of Ms. Zheng Yuan as company secretary, authorized representative, and legal process agent, effective September 29, 2025, with Mr. Huang Wenyau appointed to fill the vacancy [1] Group 1 - Ms. Zheng Yuan has resigned from her positions within the company [1] - Mr. Huang Wenyau has been appointed as the new company secretary, authorized representative, and legal process agent [1] - The changes in personnel will take effect on September 29, 2025 [1]